Articles On Phylogica (ASX:PYC)

Drug development company, PYC Therapeutics (PYC) has added six new precision medicines to its retinal drug development pipeline These new medicines were developed by Vision Pharma, a subsidiary of PYC, which combines the expertise of PYC a...

PYC Therapeutics (PYC) recently finalised its lead drug molecule in the final quarter of 2019 Its lead drug is a treatment for a type of Retinitis Pigmentosa, which is the main cause of childhood blindness The company is hoping to start th...

There are many reasons why a company might change its name, from being taken over to hiding a shady past. This year 114 companies have changed their name. Family cyber security provider Wangle Technologies became the much more fitting Famil...

Did the doc say to take one pill twice daily, or two tablets once daily? When it comes to correct medication, it’s easy to get it wrong. Because of misreading instructions, forgetfulness, laziness or nasty side effects Australians aren’t es...

Did you know that a hard-working stallion ejaculates 100 times more sperm than the average bloke? Given a virile, but weary, thoroughbred can service hundreds of mares in a breeding season, that’s just as well. But even the most virile of t...

One director has this week put more skin in the game to take his family’s total stake to over $20m — not bad. Nathan Mitchell began with the Mitchell Group in 1989, gradually working his way up the ladder. It is an investment company which...

Ever since the advent of TV, worried parents have cautioned their kids that too much time in front of John Logie Baird’s infernal device will make them go blind – a warning routinely shrugged off by the juvenile couch potatoes. It seems tha...

Biotechnology company Phylogica (ASX: PYC) is one step closer to finding a treatment for the leading cause of childhood blindness, achieving a major milestone in its human ‘retina in a dish’ study. The company today reported results from it...

On Stockhead today: Aussie small caps trying to tackle the opioid crisis, which car manufacturers will survive the EV revolution, Barry FitzGerald looks at upcoming juniors, and how South Australian small caps are putting themselves back on...

A drug delivery platform developed by biotechnology company Phylogica (ASX: PYC) has been shown to be the most effective method of administering anti-sense oligonucleotide (ASO) medications to patients with genetic eye disease. A competitiv...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Australia is known to have one of the world’s best health system, which provides quality, safe and reasonable healthcare to individuals. This is the reason which places Australia among the countries with the longest life expectancies in the...

Perth-based biotech company Phylogica (ASX: PYC) has reported positive early stage results from a pilot study of human cells using its proprietary drug delivery technology to create a treatment for blinding genetic eye diseases. The study d...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Biotechnology company Phylogica (ASX: PYC) has unveiled favourable lab results in relation to its time-course studies in animals, with superior performance to current benchmarks officially confirmed. The most recent animal model results als...

Medical tech company Phylogica (ASX: PYC) has cleared an important hurdle in the development of its patented drug delivery platform. The company’s operating focus is on improving the complex procedures used to transmit drugs to the eye. Ear...